Revvity, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Prahlad R. Singh
- Full Time Employees
- 11,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 77 4th Avenue Waltham MA United States of America 02451
- IPO Date
- Jul 6, 1965
- CIK
- 0000031791
- Website
- revvity.com
- Similar Companies
- Business
- Revvity, Inc. is a life sciences and diagnostics company that provides health science solutions, technologies, expertise, and services delivering comprehensive workflows from discovery to development, diagnosis, and cure. The company offers instruments, reagents, assay platforms, software, detection and imaging technologies, and automated solutions such as liquid handlers and cell counters. Its product portfolio includes specialized brands like AlphaLISA and SureFire Ultra no-wash assays, Cellometer and Celigo automated cell counters, chemagic nucleic acid extraction systems, IVIS fluorescence and bioluminescence imaging platforms, LentiBOOST for lentiviral transduction, Vanadis noninvasive prenatal testing systems, and various other reagents, consumables, and assay kits targeting life science research and clinical diagnostics markets. Revvity’s diagnostics segment focuses on reproductive health, immunodiagnostics, applied genomics, and infectious disease detection, serving hospitals, medical labs, clinicians, and research professionals globally. Founded in 1937 and headquartered in Waltham, Massachusetts, Revvity emerged in 2023 following the split of PerkinElmer, Inc., retaining the life sciences and diagnostics businesses while the remaining segments were sold to private equity. Since its spinoff, Revvity has undergone significant strategic restructuring, including reorganizing its operating model effective fiscal year 2025 to integrate its Applied Genomics business into a newly formed Life Sciences Solutions unit. The company re-segmented its operations into Life Sciences Solutions and Software, and Diagnostics, which now encompasses Immunodiagnostics and Reproductive Health. Recent innovations include the launch of AI-driven software platforms like Signals One, the IDS i20 ChLIA analyzer, and advanced imaging systems such as the Quantum GX3 targeting specialized diagnostics markets. Revvity actively pursues cost discipline and operational synergies while investing in digital transformation and AI integration to enhance productivity and competitive positioning in precision diagnostics and life sciences research. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and clinical markets worldwide. Its comprehensive offerings support translational multi-omics technologies, biomarker identification, molecular imaging, immunoassays, molecular diagnostics, and genomic workflows with a focus on oncology, immunology, personalized medicine, and early disease detection. The company operates across North America, Europe, and other global regions, driven by innovation in reproductive health science, immune system disorder diagnostics, and genetic disorder testing. With a workforce exceeding 11,000 employees, Revvity continues to expand its product portfolio and technological capabilities to remain a leader in biotechnology, diagnostics, and life sciences markets.
Company News
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
What Makes Revvity (RVTY) a New Buy Stock
Bank of New York Mellon Corp Invests $78.77 Million in Revvity Inc. $RVTY
Is the Options Market Predicting a Spike in Revvity Stock?
Revvity Inc (RVTY) Shares Surge 5.0% -- What GF Score of 78 Tells Investors
Assenagon Asset Management S.A. Has $1.72 Million Stock Position in Revvity Inc. $RVTY
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
Revvity Inc. $RVTY Shares Acquired by Cetera Investment Advisers
Revvity to Present at Upcoming Investor Conferences
Revvity to Present at Upcoming Investor Conferences
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
Revvity Q2 Earnings Call Highlights
RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up
Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript
Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates
Is Revvity Inc (RVTY) Undervalued? Q2 Earnings Report Shows GAAP EPS at $0.48 and Revenue Reaches $730 Million -- GF Score 75/100
Revvity Announces Financial Results for the Second Quarter of 2026
Revvity Board Declares Quarterly Dividend
Revvity to Report Q2 Earnings: What's in Store for the Stock?